Cochrane Abstracts
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Biologic or Tofacitinib Monotherapy for Rheumatoid Arthritis in People With Traditional Disease‐modifying Anti‐rheumatic Drug (DMARD) Failure: a Cochrane Systematic Review and Network Meta‐analysis (NMA)." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434773/all/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA_.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA). Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434773/all/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA_. Accessed January 19, 2025.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA). (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434773/all/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA_
Biologic or Tofacitinib Monotherapy for Rheumatoid Arthritis in People With Traditional Disease‐modifying Anti‐rheumatic Drug (DMARD) Failure: a Cochrane Systematic Review and Network Meta‐analysis (NMA) [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434773/all/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)
ID - 434773
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434773/all/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA_
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
